M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal BioSpaceOf the 13 programs that the companies will advance, four will come from Hengrui Pharma and four from Bristol Myers Squibb.OncologyRead full story pharminent May 12, 2026 (Last updated: May 12, 2026) BioSpace Of the 13 programs that the companies will advance, four will come from Hengrui Pharma and four from Bristol Myers Squibb. Oncology Read full story Post navigation Previous: EU agrees plan to tackle essential medicine shortagesNext: Next Post Related Stories M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026 M&A / Deals Lilly, Gilead lead pharma’s M&A boom pharminent May 8, 2026 M&A / Deals Odyssey launches upsized $279M IPO, Seaport docks on Nasdaq pharminent May 8, 2026
